Pfizer to discontinue popular Corex cough syrup; retain brand

Pfizer will be discontinuing its popular Corex cough syrup but will retain the 'Corex' brand for future line extensions, the pharmaceutical told the BSE in a notification on Tuesday. The decision was taken after comprehensive tests of its respiratory products, it said. 

"The company has decided to discontinue the manufacturing of the current Corex Cough Syrup formulation *Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg)."

However, Pfizer clarified that it stood by the safety and efficacy of the current Corex Cough Syrup formulation that has been duly approved by the central and state regulators. 

"Pfizer Limited has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company will launch additional products while it may also discontinue the manufacture of certain SKUs (stock keeping units) where needed. 

With the first launch in December this yaer, the company will go on to launch a series of products as line extensions under the Corex brand name, the company told BSE. "As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place," the company told the BSE. 

At 1516, the company's shares were trading at Rs 1,823.75, up Rs 12.90 or 0,71% from previous day's close.